PAPERS DISCUSSED BY DR KIM (LUNG, HEAD & NECK AND THYROID CANCER)

Pirker R et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 2008;Abstract 3.

Schiller JH et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. Proc ASCO 2008;Abstract 8014.

Karp DD et al. High activity of the anti-IGFIR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. Proc ASCO 2008;Abstract 8015.

Riely GJ et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Proc ASCO 2008;Abstract 8006.

Douillard J-Y et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). Proc ASCO 2008;Abstract 8001.

Socinski MA et al. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). Proc ASCO 2008;Abstract 7517.

Akerley WL et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. Proc ASCO 2008;Abstract 8043.

Paccagnella A et al. Concomitant chemoradiotherapy (CT/RT) vs neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study. Proc ASCO 2008;Abstract 6000.

Tishler RB et al. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. Proc ASCO 2008;Abstract 6001.

Argiris A et al. Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). Proc ASCO 2008;Abstract 6002.

Haddad RI et al. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Proc ASCO 2008;Abstract 6024.

Brose MS et al. A phase II study of sorafenib in metastatic thyroid carcinoma. Proc ASCO 2008;Abstract 6026.

Ahmed M et al. Preliminary results of an open labeled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer. Proc ASCO 2008;Abstract 6060.